遺伝子組換え凝固因子の世界市場

遺伝子組換え凝固因子の世界市場は2030年までに米国で195億米ドルに達する見込み

2024年に145億米ドルと推定される遺伝子組換え凝固因子の世界市場は、分析期間2024-2030年にCAGR 5.1%で成長し、2030年には195億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである遺伝子組換え第VIII因子は、CAGR 5.6%を記録し、分析期間終了時には117億米ドルに達すると予測されます。遺伝子組換え第IX因子セグメントの成長率は、分析期間中CAGR 3.8%と推定されます。

米国市場は40億米ドルと推定、中国はCAGR 8.1％で成長すると予測

米国の遺伝子組換え凝固因子市場は、2024年に40億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに39億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは8.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.4%と5.1%と予測されています。欧州では、ドイツがCAGR 3.3%で成長すると予測されています。

世界の遺伝子組換え凝固因子市場- 主要動向と促進要因のまとめ

遺伝子組み換え技術は凝固療法をどのように再構築しているか？

血液学の分野は、特に血友病やその他の出血性疾患の治療に使用される凝固因子の生産において、組み換え技術の進歩によって大きく変貌しています。血漿由来の治療薬とは異なり、遺伝子組換え凝固因子は遺伝子操作された細胞株を用いて合成されるため、血液媒介病原体に関連するリスクが排除されます。この技術的飛躍により、特に小児や免疫不全集団における第VIII因子および第IX因子治療の安全性プロファイルが改善されました。さらに、ヒトや動物のタンパク質を含まない第3世代の遺伝子組換え型因子の採用が増加しており、新興国市場全体で臨床的信頼と規制当局の受け入れが強化されています。

さらに、輸注回数を減らし、患者のアドヒアランスを向上させるために設計された、半減期が延長されたリコンビナント製剤にも技術革新が見られます。PEG化や融合タンパク質技術によって達成されるこれらの改変は、治療効果を損なうことなく薬物動態を向上させる。遺伝子治療研究の進歩に伴い、遺伝子組換えプラットフォームは、特に遺伝子導入治療がコスト的に困難であるか、臨床評価段階にある地域において、予防的治療やオンデマンド治療の主流となっています。コストに敏感な市場ではバイオシミラー医薬品の参入が盛んになっており、状況はオリジネーター製品以外にも拡大しつつあります。

どのような臨床的・患者中心のシフトが市場を拡大しているのか？

予防医療と患者のQOL重視の高まりは、遺伝子組換え凝固因子の使用ダイナミクスを大きく変化させています。臨床医は現在、反応的なイベントベースの輸注よりも、一定の因子レベルを維持する長期予防レジメンを好んでいます。このシフトは、予防的投与が長期にわたって関節損傷、入院率、総ヘルスケアコストを減少させることを証明するエビデンスの増加によって裏付けられています。このような臨床的嗜好の変化は、治療の利便性を高め、患者が自律的に病状を管理できるようにする皮下投与製剤や在宅輸液プロトコルの開発を刺激しています。

同時に、新興市場における新生児スクリーニング・プログラムや早期診断の枠組みの拡大により、遺伝子組換え療法の対象となる患者層が拡大しています。アドボカシー団体や政府主導のイニシアチブによる疾患認知の高まりは、以前は報告不足や誤った管理下にあった軽症や中等症の診断改善につながりました。小児における遺伝子組換え因子の使用は、有利な償還制度や、血漿由来の代替品と比較して阻害因子の発現が少ないことを強調するデータに支えられて、牽引力を増しています。この動向は、多国籍バイオファーマ企業との戦略的提携を通じて国内の血友病医療水準を向上させている中所得国において特に顕著です。

製造能力とサプライチェーンダイナミクスが果たす役割とは？

製造のスケーラビリティとコールドチェーン物流は、遺伝子組換え凝固因子市場におけるアクセスとアフォーダビリティを形成する上で中心的な役割を果たします。これらの生物製剤の製造には、高収率発現システム、厳密な精製プロトコール、検証された無菌条件が必要です。確立された生産プラットフォームと強力な規制上の実績を有する企業は、特に南アジアや東欧のような普及率の高い地域において、世界の需要の高まりに対応するのに有利な立場にあります。特に中国とインドにおける最近の生産能力拡張は、国内のニーズをサポートすることを目的としている一方で、コスト効率を求める欧米企業の受託製造ハブとしての役割も果たしています。

流通インフラと温度管理されたロジスティクスは、特にヘルスケアへのアクセスが不安定な熱帯地域や農村部では、製品の安定性を確保するために依然として不可欠です。凍結乾燥製剤や再製剤化製剤の進歩は、製品の保存期間や現場での使いやすさを改善することで、こうした課題を軽減するのに役立っています。さらに、NGOや国際援助プログラム（世界血友病連盟の人道援助プログラムなど）との協力により、十分なサービスが提供されていない地域での組換え製剤の利用可能性が拡大しています。このようなパートナーシップは、価格設定戦略と相まって市場参入障壁を下げ、伝統的な高所得者層市場以外の段階的成長に拍車をかけています。

この市場の持続的拡大の原動力は何か？

遺伝子組換え凝固因子市場の成長は、遺伝子組換え技術の絶え間ない革新、予防的治療を支持する治療パラダイムの進化、血液療法への世界のアクセスの拡大など、いくつかの要因によって牽引されています。半減期延長製剤の利用可能性が高まっていることは、投与スケジュールと患者の転帰を改善する重要な起爆剤となっています。さらに、治療センターやレジストリーを含む血友病インフラへの投資が増加し、早期診断と計画的な長期治療が可能になり、対応可能な治療人口が増加しています。

バイオ医薬品企業もまた、稀な出血性疾患や阻害剤耐性の出血性疾患に対応できる新規組換え因子のパイプライン開発を加速させています。これと並行して、バイオシミラーに対する有利な規制上の道筋や薬剤経済学的評価の改善により、市場競争力が拡大し、単価が下がり、支払者の採用が促進されています。デジタル輸液トラッキング、遠隔モニタリングのための遠隔医療、AIベースの投与アルゴリズムなどの技術統合は、組換え療法をより正確かつ個別化し、長期服薬アドヒアランスを強化しています。

地域的な成長は、政策的インセンティブ、国家調達プログラム、量よりも成果に報いる価値ベースの償還枠組みによってさらに支えられています。世界の医療制度が非伝染性疾患管理を優先する中、遺伝子組換え凝固因子は最新の出血性疾患治療の要として位置づけられています。これらの要因が、世界の遺伝子組換え凝固因子市場の堅調かつ持続的な成長を支えています。

セグメント

製品タイプ（遺伝子組換え第VIII因子、遺伝子組換え第IX因子、フォンウィルブランド因子）、血友病タイプ（血友病A、血友病B）、エンドユーザー（病院、クリニック、研究機関）

調査対象企業の例

• Albumedix Ltd.
• Bayer AG
• Baxter International Inc.
• BDI Pharma, Inc.
• Biogen Inc.
• CSL Behring（CSL Limited）
• Emergent BioSolutions Inc.
• Genzyme（Sanofi Genzyme）
• Grifols, S.A.
• Green Cross Corporation
• Kedrion S.p.A.
• LFB S.A.
• Novo Nordisk A/S
• Octapharma AG
• Pfizer Inc.
• Prometic Life Sciences Inc.
• Sanofi S.A.
• Shire（now part of Takeda）
• Swedish Orphan Biovitrum AB（Sobi）
• Takeda Pharmaceutical Company

AI統合

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Recombinant Coagulation Factors Market to Reach US$19.5 Billion by 2030

The global market for Recombinant Coagulation Factors estimated at US$14.5 Billion in the year 2024, is expected to reach US$19.5 Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Recombinant Factor VIII, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$11.7 Billion by the end of the analysis period. Growth in the Recombinant Factor IX segment is estimated at 3.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.0 Billion While China is Forecast to Grow at 8.1% CAGR

The Recombinant Coagulation Factors market in the U.S. is estimated at US$4.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.9 Billion by the year 2030 trailing a CAGR of 8.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 5.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Global Recombinant Coagulation Factors Market - Key Trends & Drivers Summarized

How Are Recombinant Technologies Reshaping Coagulation Therapies?

The field of hematology has been significantly transformed by the advancement of recombinant technologies, particularly in the production of coagulation factors used for managing hemophilia and other bleeding disorders. Unlike plasma-derived therapies, recombinant coagulation factors are synthesized using genetically engineered cell lines, eliminating the risks associated with blood-borne pathogens. This technological leap has improved the safety profile of factor VIII and IX treatments, especially among pediatric and immunocompromised populations. Moreover, the increasing adoption of third-generation recombinant factors-which are free from human and animal proteins-has strengthened clinical confidence and regulatory acceptance across developed markets.

Further innovation is observed in extended half-life recombinant products, designed to reduce the frequency of infusions and improve patient adherence. These modifications, achieved via PEGylation or fusion protein technology, enhance pharmacokinetics without compromising therapeutic efficacy. As gene therapy research advances, recombinant platforms remain the dominant standard for prophylactic and on-demand treatments, particularly in regions where gene transfer therapies are either cost-prohibitive or still under clinical evaluation. With biosimilar entrants gaining traction in cost-sensitive markets, the landscape is expanding beyond originator products, promoting broader access and supporting health system sustainability.

Which Clinical and Patient-Centric Shifts Are Expanding the Market?

The growing emphasis on prophylactic care and patient quality of life is substantially altering the usage dynamics of recombinant coagulation factors. Clinicians are now favoring long-term preventive regimens that maintain consistent factor levels rather than reactive, event-based infusions. This shift is supported by a growing body of evidence demonstrating that prophylaxis reduces joint damage, hospitalization rates, and total healthcare costs over time. These evolving clinical preferences are stimulating the development of subcutaneous formulations and home-based infusion protocols, which enhance treatment convenience and empower patients to manage their condition autonomously.

At the same time, the expansion of neonatal screening programs and early diagnostic frameworks across emerging markets is widening the eligible patient base for recombinant therapies. Rising disease awareness, driven by advocacy groups and government-led initiatives, has led to improved diagnosis of mild and moderate cases that were previously underreported or mismanaged. Pediatric use of recombinant factors is gaining traction, supported by favorable reimbursement schemes and data highlighting reduced inhibitor development compared to plasma-derived alternatives. This trend is particularly pronounced in middle-income countries upgrading their national hemophilia care standards through strategic alliances with multinational biopharma firms.

What Role Do Manufacturing Capabilities and Supply Chain Dynamics Play?

Manufacturing scalability and cold-chain logistics play a central role in shaping access and affordability in the recombinant coagulation factors market. Biomanufacturing of these biologics requires high-yield expression systems, rigorous purification protocols, and validated aseptic conditions. Companies with established production platforms and strong regulatory track records are better positioned to meet rising global demand, particularly in high-prevalence regions such as South Asia and Eastern Europe. Recent capacity expansions, especially in China and India, are geared toward supporting domestic needs while also serving as contract manufacturing hubs for Western firms seeking cost efficiency.

Distribution infrastructure and temperature-controlled logistics remain critical for product stability, particularly in tropical and rural areas with unreliable healthcare access. Advances in lyophilized and ready-to-reconstitute formulations are helping mitigate these challenges by improving product shelf-life and field usability. Moreover, collaborations with NGOs and international aid programs-such as the World Federation of Hemophilia’s Humanitarian Aid Program-are extending recombinant product availability in underserved regions. These partnerships, combined with pricing-tier strategies, are lowering market entry barriers and fueling incremental growth beyond traditional high-income markets.

What Is Driving the Sustained Expansion of This Market?

The growth in the recombinant coagulation factors market is driven by several factors, including continuous innovation in recombinant technologies, evolving treatment paradigms favoring prophylactic care, and expanding global access to hematologic therapies. The increasing availability of extended half-life products is a key catalyst, offering improved dosing schedules and patient outcomes. Furthermore, rising investments in hemophilia infrastructure, including treatment centers and registries, are enabling earlier diagnosis and structured long-term care-thereby increasing the addressable treatment population.

Biopharmaceutical firms are also accelerating pipeline development for novel recombinant factors that can address rare and inhibitor-resistant bleeding disorders. Parallel to this, favorable regulatory pathways for biosimilars and improved pharmacoeconomic evaluations are expanding market competitiveness, lowering unit costs, and facilitating payer adoption. Technological integration-such as digital infusion tracking, telemedicine for remote monitoring, and AI-based dosing algorithms-is making recombinant therapy more precise and personalized, reinforcing long-term adherence.

Regional growth is further supported by policy incentives, national procurement programs, and value-based reimbursement frameworks that reward outcomes over volume. As global health systems prioritize non-communicable disease management, recombinant coagulation factors are positioned as a cornerstone of modern bleeding disorder care. Collectively, these drivers underpin the robust and sustained trajectory of the global recombinant coagulation factors market.

SCOPE OF STUDY:

The report analyzes the Recombinant Coagulation Factors market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Recombinant Factor VIII, Recombinant Factor IX, Von Willebrand Factor); Hemophilia Type (Hemophilia A, Hemophilia B); End-Use (Hospitals End-Use, Clinics End-Use, Research Organization End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

• Albumedix Ltd.
• Bayer AG
• Baxter International Inc.
• BDI Pharma, Inc.
• Biogen Inc.
• CSL Behring (CSL Limited)
• Emergent BioSolutions Inc.
• Genzyme (Sanofi Genzyme)
• Grifols, S.A.
• Green Cross Corporation
• Kedrion S.p.A.
• LFB S.A.
• Novo Nordisk A/S
• Octapharma AG
• Pfizer Inc.
• Prometic Life Sciences Inc.
• Sanofi S.A.
• Shire (now part of Takeda)
• Swedish Orphan Biovitrum AB (Sobi)
• Takeda Pharmaceutical Company

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Recombinant Coagulation Factors - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Growing Prevalence of Hemophilia Throws the Spotlight on Recombinant Coagulation Factor Therapies
  • Rising Awareness Around Rare Bleeding Disorders Propels Growth in Recombinant Factor Markets
  • Shift from Plasma-Derived to Recombinant Therapies Strengthens Business Case for Biotech-Derived Coagulation Factors
  • Expanding Global Access to Hemophilia Diagnostics Spurs Demand for Recombinant Coagulation Products
  • Advancements in Cell Line Engineering Expand Addressable Market Opportunity for Recombinant Factor IX and VIII
  • Increasing Support from National Hemophilia Foundations Drives Adoption of Long-Acting Recombinant Therapies
  • Ongoing Transition to Prophylactic Treatment Regimens Generates Demand for Sustained Release Recombinant Products
  • Regulatory Push for Safer Biologic Alternatives Spurs Innovation in Recombinant Coagulation Factor Manufacturing
  • Improved Healthcare Infrastructure in Emerging Markets Expands Demand for Recombinant Clotting Therapies
  • Integration of Gene Therapy Trials with Factor Replacement Protocols Reshapes Market Growth Trajectories
  • Rising Incidence of Acquired Hemophilia Strengthens Demand for Next-Generation Recombinant Factor VIIa
  • Collaborative Public-Private R&D Programs Propel Innovation in Recombinant Coagulation Technologies
  • Patient-Centric Dosing Protocols Drive Preference for Recombinant Coagulation Factor Concentrates
  • Surge in Orphan Drug Designations Expands Pipeline Activity for Recombinant Blood Disorder Treatments
  • Post-COVID Recovery in Hospital-Based Infusion Services Sustains Growth Momentum in Recombinant Factor Sales
  • Emergence of Personalized Medicine Drives Innovation in Recombinant Coagulation Therapy Customization
  • Growing Cost Competitiveness of Recombinant Products Spurs Market Share Gains over Plasma-Derived Alternatives
  • Hematology Centers of Excellence Strengthen Adoption Rates of Recombinant Factor Therapies
  • Advancements in Recombinant Purification and Expression Systems Optimize Product Yields and Safety
  • Payer Emphasis on Cost-Effective Therapies Generates Demand for Biosimilar Recombinant Coagulation Products
  • Global Harmonization of Biologic Regulatory Frameworks Facilitates Faster Market Entry for Recombinant Factors
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recombinant Coagulation Factors Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Recombinant Coagulation Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Recombinant Coagulation Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Recombinant Factor VIII by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Recombinant Factor VIII by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Recombinant Factor VIII by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Recombinant Factor IX by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Recombinant Factor IX by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Recombinant Factor IX by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Von Willebrand Factor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Von Willebrand Factor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Von Willebrand Factor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Hemophilia A by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Hemophilia A by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Hemophilia A by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Hemophilia B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Hemophilia B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Hemophilia B by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Research Organization End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Research Organization End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Research Organization End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Recombinant Coagulation Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 29: USA Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: USA 16-Year Perspective for Recombinant Coagulation Factors by Product Type - Percentage Breakdown of Value Sales for Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor for the Years 2014, 2025 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: USA 16-Year Perspective for Recombinant Coagulation Factors by Hemophilia Type - Percentage Breakdown of Value Sales for Hemophilia A and Hemophilia B for the Years 2014, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: USA 16-Year Perspective for Recombinant Coagulation Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Organization End-Use for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: Canada 16-Year Perspective for Recombinant Coagulation Factors by Product Type - Percentage Breakdown of Value Sales for Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor for the Years 2014, 2025 & 2030
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: Canada 16-Year Perspective for Recombinant Coagulation Factors by Hemophilia Type - Percentage Breakdown of Value Sales for Hemophilia A and Hemophilia B for the Years 2014, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: Canada 16-Year Perspective for Recombinant Coagulation Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Organization End-Use for the Years 2014, 2025 & 2030
• JAPAN
  • Recombinant Coagulation Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: Japan 16-Year Perspective for Recombinant Coagulation Factors by Product Type - Percentage Breakdown of Value Sales for Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor for the Years 2014, 2025 & 2030
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: Japan 16-Year Perspective for Recombinant Coagulation Factors by Hemophilia Type - Percentage Breakdown of Value Sales for Hemophilia A and Hemophilia B for the Years 2014, 2025 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: Japan 16-Year Perspective for Recombinant Coagulation Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Organization End-Use for the Years 2014, 2025 & 2030
• CHINA
  • Recombinant Coagulation Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 56: China Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: China Historic Review for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: China 16-Year Perspective for Recombinant Coagulation Factors by Product Type - Percentage Breakdown of Value Sales for Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor for the Years 2014, 2025 & 2030
  • TABLE 59: China Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: China 16-Year Perspective for Recombinant Coagulation Factors by Hemophilia Type - Percentage Breakdown of Value Sales for Hemophilia A and Hemophilia B for the Years 2014, 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: China 16-Year Perspective for Recombinant Coagulation Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Organization End-Use for the Years 2014, 2025 & 2030
• EUROPE
  • Recombinant Coagulation Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Recombinant Coagulation Factors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: Europe 16-Year Perspective for Recombinant Coagulation Factors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: Europe 16-Year Perspective for Recombinant Coagulation Factors by Product Type - Percentage Breakdown of Value Sales for Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor for the Years 2014, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: Europe 16-Year Perspective for Recombinant Coagulation Factors by Hemophilia Type - Percentage Breakdown of Value Sales for Hemophilia A and Hemophilia B for the Years 2014, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Recombinant Coagulation Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Organization End-Use for the Years 2014, 2025 & 2030
• FRANCE
  • Recombinant Coagulation Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 77: France Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: France Historic Review for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: France 16-Year Perspective for Recombinant Coagulation Factors by Product Type - Percentage Breakdown of Value Sales for Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor for the Years 2014, 2025 & 2030
  • TABLE 80: France Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: France 16-Year Perspective for Recombinant Coagulation Factors by Hemophilia Type - Percentage Breakdown of Value Sales for Hemophilia A and Hemophilia B for the Years 2014, 2025 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: France 16-Year Perspective for Recombinant Coagulation Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Organization End-Use for the Years 2014, 2025 & 2030
• GERMANY
  • Recombinant Coagulation Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 86: Germany Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Germany Historic Review for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: Germany 16-Year Perspective for Recombinant Coagulation Factors by Product Type - Percentage Breakdown of Value Sales for Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor for the Years 2014, 2025 & 2030
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: Germany 16-Year Perspective for Recombinant Coagulation Factors by Hemophilia Type - Percentage Breakdown of Value Sales for Hemophilia A and Hemophilia B for the Years 2014, 2025 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: Germany 16-Year Perspective for Recombinant Coagulation Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Organization End-Use for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 95: Italy Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Italy Historic Review for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: Italy 16-Year Perspective for Recombinant Coagulation Factors by Product Type - Percentage Breakdown of Value Sales for Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor for the Years 2014, 2025 & 2030
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Italy 16-Year Perspective for Recombinant Coagulation Factors by Hemophilia Type - Percentage Breakdown of Value Sales for Hemophilia A and Hemophilia B for the Years 2014, 2025 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Italy 16-Year Perspective for Recombinant Coagulation Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Organization End-Use for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Recombinant Coagulation Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 104: UK Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: UK Historic Review for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: UK 16-Year Perspective for Recombinant Coagulation Factors by Product Type - Percentage Breakdown of Value Sales for Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor for the Years 2014, 2025 & 2030
  • TABLE 107: UK Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: UK 16-Year Perspective for Recombinant Coagulation Factors by Hemophilia Type - Percentage Breakdown of Value Sales for Hemophilia A and Hemophilia B for the Years 2014, 2025 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: UK 16-Year Perspective for Recombinant Coagulation Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Organization End-Use for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 113: Spain Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Spain Historic Review for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: Spain 16-Year Perspective for Recombinant Coagulation Factors by Product Type - Percentage Breakdown of Value Sales for Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor for the Years 2014, 2025 & 2030
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: Spain 16-Year Perspective for Recombinant Coagulation Factors by Hemophilia Type - Percentage Breakdown of Value Sales for Hemophilia A and Hemophilia B for the Years 2014, 2025 & 2030
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: Spain 16-Year Perspective for Recombinant Coagulation Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Organization End-Use for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 122: Russia Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Russia Historic Review for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: Russia 16-Year Perspective for Recombinant Coagulation Factors by Product Type - Percentage Breakdown of Value Sales for Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor for the Years 2014, 2025 & 2030
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: Russia 16-Year Perspective for Recombinant Coagulation Factors by Hemophilia Type - Percentage Breakdown of Value Sales for Hemophilia A and Hemophilia B for the Years 2014, 2025 & 2030
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: Russia 16-Year Perspective for Recombinant Coagulation Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Organization End-Use for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Rest of Europe Historic Review for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: Rest of Europe 16-Year Perspective for Recombinant Coagulation Factors by Product Type - Percentage Breakdown of Value Sales for Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor for the Years 2014, 2025 & 2030
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 16-Year Perspective for Recombinant Coagulation Factors by Hemophilia Type - Percentage Breakdown of Value Sales for Hemophilia A and Hemophilia B for the Years 2014, 2025 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 16-Year Perspective for Recombinant Coagulation Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Organization End-Use for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Recombinant Coagulation Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 141: Asia-Pacific Historic Review for Recombinant Coagulation Factors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Asia-Pacific 16-Year Perspective for Recombinant Coagulation Factors by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 16-Year Perspective for Recombinant Coagulation Factors by Product Type - Percentage Breakdown of Value Sales for Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor for the Years 2014, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 16-Year Perspective for Recombinant Coagulation Factors by Hemophilia Type - Percentage Breakdown of Value Sales for Hemophilia A and Hemophilia B for the Years 2014, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 16-Year Perspective for Recombinant Coagulation Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Organization End-Use for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Recombinant Coagulation Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 152: Australia Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Australia Historic Review for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: Australia 16-Year Perspective for Recombinant Coagulation Factors by Product Type - Percentage Breakdown of Value Sales for Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor for the Years 2014, 2025 & 2030
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Australia 16-Year Perspective for Recombinant Coagulation Factors by Hemophilia Type - Percentage Breakdown of Value Sales for Hemophilia A and Hemophilia B for the Years 2014, 2025 & 2030
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Australia 16-Year Perspective for Recombinant Coagulation Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Organization End-Use for the Years 2014, 2025 & 2030
• INDIA
  • Recombinant Coagulation Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 161: India Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: India Historic Review for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: India 16-Year Perspective for Recombinant Coagulation Factors by Product Type - Percentage Breakdown of Value Sales for Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor for the Years 2014, 2025 & 2030
  • TABLE 164: India Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: India 16-Year Perspective for Recombinant Coagulation Factors by Hemophilia Type - Percentage Breakdown of Value Sales for Hemophilia A and Hemophilia B for the Years 2014, 2025 & 2030
  • TABLE 167: India Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: India 16-Year Perspective for Recombinant Coagulation Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Organization End-Use for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 170: South Korea Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: South Korea Historic Review for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: South Korea 16-Year Perspective for Recombinant Coagulation Factors by Product Type - Percentage Breakdown of Value Sales for Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor for the Years 2014, 2025 & 2030
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: South Korea 16-Year Perspective for Recombinant Coagulation Factors by Hemophilia Type - Percentage Breakdown of Value Sales for Hemophilia A and Hemophilia B for the Years 2014, 2025 & 2030
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: South Korea 16-Year Perspective for Recombinant Coagulation Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Organization End-Use for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Asia-Pacific Historic Review for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: Rest of Asia-Pacific 16-Year Perspective for Recombinant Coagulation Factors by Product Type - Percentage Breakdown of Value Sales for Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor for the Years 2014, 2025 & 2030
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Recombinant Coagulation Factors by Hemophilia Type - Percentage Breakdown of Value Sales for Hemophilia A and Hemophilia B for the Years 2014, 2025 & 2030
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Recombinant Coagulation Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Organization End-Use for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Recombinant Coagulation Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 188: Latin America Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 189: Latin America Historic Review for Recombinant Coagulation Factors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: Latin America 16-Year Perspective for Recombinant Coagulation Factors by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Latin America 16-Year Perspective for Recombinant Coagulation Factors by Product Type - Percentage Breakdown of Value Sales for Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor for the Years 2014, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Latin America 16-Year Perspective for Recombinant Coagulation Factors by Hemophilia Type - Percentage Breakdown of Value Sales for Hemophilia A and Hemophilia B for the Years 2014, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: Latin America 16-Year Perspective for Recombinant Coagulation Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Organization End-Use for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 200: Argentina Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Argentina Historic Review for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: Argentina 16-Year Perspective for Recombinant Coagulation Factors by Product Type - Percentage Breakdown of Value Sales for Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor for the Years 2014, 2025 & 2030
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Argentina 16-Year Perspective for Recombinant Coagulation Factors by Hemophilia Type - Percentage Breakdown of Value Sales for Hemophilia A and Hemophilia B for the Years 2014, 2025 & 2030
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Argentina 16-Year Perspective for Recombinant Coagulation Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Organization End-Use for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 209: Brazil Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Brazil Historic Review for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Brazil 16-Year Perspective for Recombinant Coagulation Factors by Product Type - Percentage Breakdown of Value Sales for Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor for the Years 2014, 2025 & 2030
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Brazil 16-Year Perspective for Recombinant Coagulation Factors by Hemophilia Type - Percentage Breakdown of Value Sales for Hemophilia A and Hemophilia B for the Years 2014, 2025 & 2030
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: Brazil 16-Year Perspective for Recombinant Coagulation Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Organization End-Use for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 218: Mexico Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Mexico Historic Review for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 220: Mexico 16-Year Perspective for Recombinant Coagulation Factors by Product Type - Percentage Breakdown of Value Sales for Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor for the Years 2014, 2025 & 2030
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 223: Mexico 16-Year Perspective for Recombinant Coagulation Factors by Hemophilia Type - Percentage Breakdown of Value Sales for Hemophilia A and Hemophilia B for the Years 2014, 2025 & 2030
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 226: Mexico 16-Year Perspective for Recombinant Coagulation Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Organization End-Use for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Rest of Latin America Historic Review for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 229: Rest of Latin America 16-Year Perspective for Recombinant Coagulation Factors by Product Type - Percentage Breakdown of Value Sales for Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor for the Years 2014, 2025 & 2030
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 16-Year Perspective for Recombinant Coagulation Factors by Hemophilia Type - Percentage Breakdown of Value Sales for Hemophilia A and Hemophilia B for the Years 2014, 2025 & 2030
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 16-Year Perspective for Recombinant Coagulation Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Organization End-Use for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Recombinant Coagulation Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 236: Middle East Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 237: Middle East Historic Review for Recombinant Coagulation Factors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 238: Middle East 16-Year Perspective for Recombinant Coagulation Factors by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 241: Middle East 16-Year Perspective for Recombinant Coagulation Factors by Product Type - Percentage Breakdown of Value Sales for Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor for the Years 2014, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 244: Middle East 16-Year Perspective for Recombinant Coagulation Factors by Hemophilia Type - Percentage Breakdown of Value Sales for Hemophilia A and Hemophilia B for the Years 2014, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 247: Middle East 16-Year Perspective for Recombinant Coagulation Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Organization End-Use for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 248: Iran Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Iran Historic Review for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 250: Iran 16-Year Perspective for Recombinant Coagulation Factors by Product Type - Percentage Breakdown of Value Sales for Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor for the Years 2014, 2025 & 2030
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 253: Iran 16-Year Perspective for Recombinant Coagulation Factors by Hemophilia Type - Percentage Breakdown of Value Sales for Hemophilia A and Hemophilia B for the Years 2014, 2025 & 2030
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 256: Iran 16-Year Perspective for Recombinant Coagulation Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Organization End-Use for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 257: Israel Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Israel Historic Review for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 259: Israel 16-Year Perspective for Recombinant Coagulation Factors by Product Type - Percentage Breakdown of Value Sales for Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor for the Years 2014, 2025 & 2030
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 262: Israel 16-Year Perspective for Recombinant Coagulation Factors by Hemophilia Type - Percentage Breakdown of Value Sales for Hemophilia A and Hemophilia B for the Years 2014, 2025 & 2030
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 265: Israel 16-Year Perspective for Recombinant Coagulation Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Organization End-Use for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Saudi Arabia Historic Review for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 268: Saudi Arabia 16-Year Perspective for Recombinant Coagulation Factors by Product Type - Percentage Breakdown of Value Sales for Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor for the Years 2014, 2025 & 2030
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 16-Year Perspective for Recombinant Coagulation Factors by Hemophilia Type - Percentage Breakdown of Value Sales for Hemophilia A and Hemophilia B for the Years 2014, 2025 & 2030
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 16-Year Perspective for Recombinant Coagulation Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Organization End-Use for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 275: UAE Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: UAE Historic Review for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 277: UAE 16-Year Perspective for Recombinant Coagulation Factors by Product Type - Percentage Breakdown of Value Sales for Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor for the Years 2014, 2025 & 2030
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 280: UAE 16-Year Perspective for Recombinant Coagulation Factors by Hemophilia Type - Percentage Breakdown of Value Sales for Hemophilia A and Hemophilia B for the Years 2014, 2025 & 2030
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 283: UAE 16-Year Perspective for Recombinant Coagulation Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Organization End-Use for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Rest of Middle East Historic Review for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 286: Rest of Middle East 16-Year Perspective for Recombinant Coagulation Factors by Product Type - Percentage Breakdown of Value Sales for Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor for the Years 2014, 2025 & 2030
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 16-Year Perspective for Recombinant Coagulation Factors by Hemophilia Type - Percentage Breakdown of Value Sales for Hemophilia A and Hemophilia B for the Years 2014, 2025 & 2030
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 16-Year Perspective for Recombinant Coagulation Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Organization End-Use for the Years 2014, 2025 & 2030
• AFRICA
  • Recombinant Coagulation Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 293: Africa Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Africa Historic Review for Recombinant Coagulation Factors by Product Type - Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 295: Africa 16-Year Perspective for Recombinant Coagulation Factors by Product Type - Percentage Breakdown of Value Sales for Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor for the Years 2014, 2025 & 2030
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Recombinant Coagulation Factors by Hemophilia Type - Hemophilia A and Hemophilia B Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 298: Africa 16-Year Perspective for Recombinant Coagulation Factors by Hemophilia Type - Percentage Breakdown of Value Sales for Hemophilia A and Hemophilia B for the Years 2014, 2025 & 2030
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Recombinant Coagulation Factors by End-Use - Hospitals End-Use, Clinics End-Use and Research Organization End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 301: Africa 16-Year Perspective for Recombinant Coagulation Factors by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Organization End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION